Market research
APLS Apellis Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5B
- P/E ratio
- 38.35
- Analyst target
- 40.9231
- Dividend yield
- Not available
- Beta
- -0.25
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03753U1060
- Market cap
- 5B
- P/E ratio
- 38.35
- Analyst target
- 40.9231
- Dividend yield
- Not available
- Beta
- -0.25
About
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the APLS discussion.
5 years, 4 months ago
Apellis Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 45.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.
Apellis Pharmaceuticals, Inc's total revenue rose by inf% to $250M since the same quarter in the previous year.
Its net income has increased by 169.1% to $78M since the same quarter in the previous year.
Finally, its free cash flow grew by 271.8% to $141M since the same quarter in the previous year.
Based on the above factors, Apellis Pharmaceuticals, Inc gets an overall score of 5/5.